-
Net Sales are expected to increase by 5.1 percent Y-o-Y (up 1.3 percent Q-o-Q) to Rs. 6,555.2 crore, according to Prabhudas Lilladher.
-
Net Sales are expected to increase by 5.1 percent Y-o-Y (up 1.3 percent Q-o-Q) to Rs. 6,555.2 crore, according to Prabhudas Lilladher.
-
Net Sales are expected to increase by 5.1 percent Y-o-Y (up 3.2 percent Q-o-Q) to Rs 5,994.3 crore, according to ICICI Direct.
-
Net Sales are expected to increase by 4.7 percent Y-o-Y (up 2.7 percent Q-o-Q) to Rs 5,968.4 crore, according to Prabhudas Lilladher.
-
Net Sales are expected to decrease by 1.1 percent Y-o-Y (down 1.2 percent Q-o-Q) to Rs 5,932.9 crore, according to Prabhudas Lilladher.
-
Net Sales are expected to decrease by 2.7 percent Y-o-Y (up 4.2 percent Q-o-Q) to Rs 6,190.4 crore, according to Prabhudas Lilladher.
-
Net Sales are expected to decrease by 9.5 percent Y-o-Y (up 1.4 percent Q-o-Q) to Rs 5,771.5 crore, according to Prabhudas Lilladher.
-
Net Sales are expected to increase by 3.8 percent Y-o-Y (up 2.4 percent Q-o-Q) to Rs 6,148 crore, according to KRChoksey.
-
Net Sales are expected to increase by 5.2 percent Y-o-Y (up 3.9 percent Q-o-Q) to Rs 6,233.7 crore, according to ICICI Direct.
-
Net Sales are expected to increase by 8.3 percent Y-o-Y (up 4.8 percent Q-o-Q) to Rs. 6,671.2 crore, according to Sharekhan.
-
Net Sales are expected to increase by 15.5 percent Y-o-Y (up 5 percent Q-o-Q) to Rs. 5,799.4 crore, according to Prabhudas Lilladher.
-
The stock shot up 149 percent from its March lows especially after increased focus on healthcare worldwide due to COVID-19 crisis.
-
Net Sales are expected to increase by 18.8 percent Y-o-Y (up 3.7 percent Q-o-Q) to Rs. 5,645.7 crore, according to Emkay.
-
Net Sales are expected to increase by 26.5 percent Y-o-Y (down 2.8 percent Q-o-Q) to Rs. 5,121.6 crore, according to Kotak.
-
Net Sales are expected to increase by 25.9 percent Y-o-Y (down 3 percent Q-o-Q) to Rs. 5,020.7 crore, according to Prabhudas Lilladher.
-
Aurobindo has maintained its guidance of 30 percent YoY growth in injectable sales. Further, company filed 10 ANDAs, including 4 injectables, taking the cumulative ANDAs pending for approval to 122
-
The company will declare its results today. Analysts suggest one to focus on US business growth and upcoming product announcements.
-
Net Sales are expected to increase by 12.7 percent Y-o-Y (up 2.9 percent Q-o-Q) to Rs. 4,888 crore, according to Sharekhan.
-
Net Sales are expected to increase by 15.8 percent Y-o-Y (up 5.7 percent Q-o-Q) to Rs. 5,022.3 crore, according to ICICI Direct.
-
For Lupin, Credit Suisse sees margin improving but weak Tamiflu season could be an overhang.
-
Further, high R&D cost is likely to affect financials as well, one brokerage house wrote in its report.
-
Net Sales are expected to decrease by 3.9 percent Y-o-Y (up 0.3 percent Q-o-Q) to Rs. 4,260 crore, according to HDFC Securities.
-
Net Sales are expected to increase by 6.3 percent Y-o-Y (up 10.9 percent Q-o-Q) to Rs. 4,714 crore, according to Sharekhan.
-
Net Sales are expected to increase by 4.6 percent Y-o-Y (up 9.1 percent Q-o-Q) to Rs. 4,638.9 crore, according to ICICI Direct.
-
Emkay Global, in its report, observed that cycling pressure in US market will start waning ahead, but structural pressures will still persist.
